Schrödinger Q3 2026 net loss widens 15% to $37.71 million

By Public Technologies
  • Schrödinger’s third-quarter 2026 net loss widened 15% year over year to $37.71 million.
  • Total revenue rose 19% to $64.5 million, while drug discovery revenue jumped 86% to $24.19 million, primarily due to a Structure Therapeutics milestone.
  • Annual contract value climbed 17% to $44.7 million, while hosted software revenue increased 49% to $17.2 million.
  • In September, the company licensed two early-stage programs to co-founded Tectora Therapeutics for equity and eligibility for milestones and royalties.
  • Full-year 2026 guidance increased to $222 million–$232 million for annual contract value and $75 million–$85 million for drug discovery revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611041605BIZWIRE_USPR_____20261104_BW302582) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.